Literature DB >> 20587216

Oral contraceptive induced cerebral venous thrombosis treated by local catheter directed thrombolysis.

V Prochazka1, J Rajner, M Prochazka, J Dvorak, V Cizek.   

Abstract

SUMMARY: We report on a case of cerebral venous thrombosis (CVT) induced by oral contraception (OC) activated coagulopathy and its endovascular treatment. Deep venous system and dural sinuses thrombosis complicated with severe neurological deficit and coma due to right thalamic edema and ischemia in a young woman was treated by local thrombolysis with an administration of 0.6 mg/h of the rtPA and the concomitant intravenous unfractioned heparin infusion (700 IU/h). 3D-Xra digital rotational venography performed at the beginning and after treatment confirmed thrombus resolution with rapid flow restoration. Dynamic flow imaging gives interesting information on the deep venous system and the cortical venous collectors drainage. Final NIHSS (National Institute of Health Stroke Scale) and mRS (modified Rankin Scale) confirmed an excellent clinical outcome of the interventional therapy.

Entities:  

Year:  2005        PMID: 20587216      PMCID: PMC3463292          DOI: 10.1177/159101990401000406

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  22 in total

1.  Intracranial venous hemodynamics is a factor related to a favorable outcome in cerebral venous thrombosis.

Authors:  Erwin Stolz; Tibo Gerriets; Rolf H Bödeker; Monika Hügens-Penzel; Manfred Kaps
Journal:  Stroke       Date:  2002-06       Impact factor: 7.914

2.  Direct thrombolysis of superior sagittal sinus thrombosis with coexisting intracranial hemorrhage.

Authors:  J R Rael; W W Orrison; N Baldwin; J Sell
Journal:  AJNR Am J Neuroradiol       Date:  1997-08       Impact factor: 3.825

3.  Antiphospholipid antibodies: findings at arteriography.

Authors:  J M Provenzale; D P Barboriak; N B Allen; T L Ortel
Journal:  AJNR Am J Neuroradiol       Date:  1998-04       Impact factor: 3.825

4.  Diffusion-weighted MR imaging of an acute venous stroke: case report.

Authors:  E Peeters; T Stadnik; F Bissay; E Schmedding; M Osteaux
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

5.  Prothrombin gene G20210-->A transition is a risk factor for cerebral venous thrombosis.

Authors:  K H Reuner; A Ruf; A Grau; H Rickmann; E Stolz; E Jüttler; K F Druschky; H Patscheke
Journal:  Stroke       Date:  1998-09       Impact factor: 7.914

6.  Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).

Authors:  José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2004-02-19       Impact factor: 7.914

7.  Hyperhomocysteinemia, low folate and vitamin B12 concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous thrombosis.

Authors:  Carlos Cantu; Elisa Alonso; Aurelio Jara; Leticia Martínez; Camilo Ríos; María de los Angeles Fernández; Irma Garcia; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2004-06-10       Impact factor: 7.914

8.  Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients.

Authors:  P Lüdemann; D G Nabavi; R Junker; E Wolff; K Papke; H Buchner; G Assmann; E B Ringelstein
Journal:  Stroke       Date:  1998-12       Impact factor: 7.914

Review 9.  Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1998

10.  The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.

Authors:  L A Norris; J Bonnar
Journal:  Br J Obstet Gynaecol       Date:  1996-03
View more
  1 in total

1.  Cyclosporine-A-Induced Intracranial Thrombotic Complications: Systematic Review and Cases Report.

Authors:  Si-Ying Song; Zhong-Ao Wang; Yu-Chuan Ding; Xun-Ming Ji; Ran Meng
Journal:  Front Neurol       Date:  2021-02-11       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.